General Information
FORMA NASH 201
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability and Efficacy of FT-4101 in Overweigt/Obese Subjects with NASH
| Protocol | 4101-MET-201 |
|---|---|
| Identifier | |
| UID | 43f06fd2-fa7d-436d-828b-a3fb6a476abe |
| Status | Done - Archived |
| Phase | 1/2 |
| Category | NASH / Adult |
| Launch Year | 2019 |
| NCT Number | - |
| Created | 2019-05-03 13:48 |
| Last Updated | 2019-05-03 13:48 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2019-10-25 | No |
| Enrollment Open | 2019-07-19 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2019-06-24 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2020-05-05 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Gallardo, Michael | MGallardo | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Forma Therapeutics |
|---|---|
| Division | Forma Therapeutics |
| Team | Forma Therapeutics |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | ProSciento, Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
